Discovery of furyl/thienyl β-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect.

[1]  Lin Li,et al.  Terpenoids with vasorelaxant effects from the Chinese liverwort Scapania carinthiaca. , 2018, Bioorganic & medicinal chemistry.

[2]  R. Hartmann,et al.  Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors , 2018, Archiv der Pharmazie.

[3]  Jianbo Ji,et al.  Design and synthesis of furyl/thineyl pyrroloquinolones based on natural alkaloid perlolyrine, lead to the discovery of potent and selective PDE5 inhibitors. , 2018, European journal of medicinal chemistry.

[4]  Xin Wei,et al.  Inhibitors of phosphodiesterase as cancer therapeutics. , 2018, European journal of medicinal chemistry.

[5]  V. Nikolaev,et al.  cGMP Signaling in the Cardiovascular System—The Role of Compartmentation and Its Live Cell Imaging , 2018, International journal of molecular sciences.

[6]  Hai-bin Luo,et al.  Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease. , 2018, Journal of medicinal chemistry.

[7]  Feng Jiang,et al.  Rhynchophylla total alkaloid rescues autophagy, decreases oxidative stress and improves endothelial vasodilation in spontaneous hypertensive rats , 2017, Acta Pharmacologica Sinica.

[8]  P. Brust,et al.  Synthesis and in vitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes. , 2017, European journal of medicinal chemistry.

[9]  Yadan Huang,et al.  Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. , 2017, Journal of medicinal chemistry.

[10]  Serdar Durdagi,et al.  Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development , 2017, Journal of enzyme inhibition and medicinal chemistry.

[11]  Lin Li,et al.  Design, synthesis and biological evaluation of novel macrocyclic bisbibenzyl analogues as tubulin polymerization inhibitors. , 2016, European journal of medicinal chemistry.

[12]  Hai-bin Luo,et al.  Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4. , 2016, European journal of medicinal chemistry.

[13]  H. Lou,et al.  Organocatalytic Enantioselective Oxidative C-H Alkenylation and Arylation of N-Carbamoyl Tetrahydropyridines and Tetrahydro-β-carbolines. , 2015, Angewandte Chemie.

[14]  H. Ke,et al.  Advances in targeting cyclic nucleotide phosphodiesterases , 2014, Nature Reviews Drug Discovery.

[15]  Zhe Li,et al.  The Molecular Basis for the Selectivity of Tadalafil toward Phosphodiesterase 5 and 6: A Modeling Study , 2013, J. Chem. Inf. Model..

[16]  R. Deshmukh,et al.  Neuroprotective role of PDE4 and PDE5 inhibitors in 3-nitropropionic acid induced behavioral and biochemical toxicities in rats. , 2013, European journal of pharmacology.

[17]  Emmanuel S. Buys,et al.  Assessing murine resistance artery function using pressure myography. , 2013, Journal of visualized experiments : JoVE.

[18]  O. Arancio,et al.  Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. , 2013, European journal of medicinal chemistry.

[19]  R. Hartmann,et al.  Design of Novel β‐Carboline Derivatives with Pendant 5‐Bromothienyl and Their Evaluation as Phosphodiesterase‐5 Inhibitors , 2013, Archiv der Pharmazie.

[20]  P. Fossa,et al.  Docking-based CoMFA and CoMSIA analyses of tetrahydro-β-carboline derivatives as type-5 phosphodiesterase inhibitors , 2012, Journal of enzyme inhibition and medicinal chemistry.

[21]  H. Inoue,et al.  Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. , 2012, The Journal of urology.

[22]  K. Ziegelbauer,et al.  PDE5 inhibitors beyond erectile dysfunction , 2007, International Journal of Impotence Research.

[23]  C. Teixeira,et al.  Differential Effects of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Vardenafil, and Tadalafil in Rat Aorta , 2006, Journal of Pharmacology and Experimental Therapeutics.

[24]  Kam Y. J. Zhang,et al.  Structural basis for the activity of drugs that inhibit phosphodiesterases. , 2004, Structure.

[25]  Waya Sengpracha,et al.  A Revised Structure for the Alkaloid, Tribulusterine, from Tribulus terrestris L. , 2004 .

[26]  R. Labaudinière,et al.  The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues. , 2003, Journal of medicinal chemistry.

[27]  R. Labaudinière,et al.  The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues. , 2003, Journal of medicinal chemistry.

[28]  Weiqin Jiang,et al.  Synthesis and biological activities of novel beta-carbolines as PDE5 inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[29]  Andrew Henwood,et al.  Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction. , 2003, Journal of medicinal chemistry.

[30]  Weiqin Jiang,et al.  Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction. , 2002, Journal of medicinal chemistry.

[31]  J. Sportsman,et al.  A Fluorescence Polarization Assay for Cyclic Nucleotide Phosphodiesterases , 2002, Journal of biomolecular screening.

[32]  T. Lampe,et al.  Imidazo[5,1-f][1,2,4]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors , 2002 .

[33]  J. Beavo,et al.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. , 2000, Current opinion in cell biology.